Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau

Human Molecular Genetics

Volumn 24, Issue 12, 2015, Pages 3545-3556

  Mikhail, Fadi ^a   Calingasan, Noel ^a   Parolari, Luca ^a   Subramanian, Aarthi ^a   Yang, Lichuan ^a   Flint Beal, M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN; BIOLOGICAL MARKER; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN REGION; CELL LOSS; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE MUTATION; GLIOSIS; HIPPOCAMPUS; IN VIVO STUDY; MEMORY DISORDER; MOTONEURON; MOUSE; NERVE DEGENERATION; NONHUMAN; PARALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SPINAL CORD; ANIMAL; ANIMAL BEHAVIOR; CELL COUNT; CORPUS STRIATUM; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MEMORY; METABOLISM; MORTALITY; MOTOR ACTIVITY; MUTATION; NEURODEGENERATIVE DISEASES; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROTEINOSIS; TRANSGENIC MOUSE;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; BEHAVIOR, ANIMAL; BIOMARKERS; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MEMORY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; NEURODEGENERATIVE DISEASES; PHENOTYPE; PHOSPHORYLATION; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN-SERINE-THREONINE KINASES; TAU PROTEINS;

EID: 84930423131     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv105     Document Type: Article

References (59)

1. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med., 339, 1044-1053.
2. Forno, L.S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 55, 259-272.
3. Healy, D.G., Falchi, M., O'Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S. et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol., 7, 583-590.
4. Thomas, B. and Beal, M.F. (2007) Parkinson's disease. Hum. Mol. Genet., 16, R183-R194.
5. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks,W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
6. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
7. Nichols, R.J., Dzamko, N., Morrice, N.A., Campbell, D.G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R. and Alessi, D.R. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease associated mutations and regulates cytoplasmic localization. Biochem. J., 430, 393-404.
8. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J., Dawson, V.L. and Dawson, T.M. (2010) Inhibitors of leucine- rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med., 16, 998-1000.
9. Gehrke, S., Imai, Y., Sokol, N. and Lu, B. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature, 466, 637-641.
10. Imai, Y., Gehrke, S.,Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 27, 2432-2443.
11. Lee, S., Liu, H.P., Lin, W.Y., Guo, H. and Lu, B. (2010) LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the neuromuscular junction. J. Neurosci., 30, 16959-16969.
12. MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B.D., Marder, K.S., Honig, L.S., Clark, L.N., Small, S.A. and Abeliovich, A. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron, 77, 425-439.
13. Migheli, R., Del Giudice, M.G., Spissu, Y., Sanna, G., Xiong, Y., Dawson, T.M., Dawson, V.L., Galioto, M., Rocchitta, G., Biosa, A. et al. (2013) LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS ONE, 8, e77198.
14. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA, 102, 16842-16847.
15. Li, X., Tan, Y.C., Poulose, S., Olanow, C.W., Huang, X.Y. and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem., 103, 238-247.
16. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 46, 1380-1388.
17. Haugarvoll, K. and Wszolek, Z.K. (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism Relat. Disord., 15(Suppl.3), S205-S208.
18. Ballatore, C., Lee, V.M. and Trojanowski, J.Q. (2007) Taumediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci., 8, 663-672.
19. Ludolph, A.C., Kassubek, J., Landwehrmeyer, B.G., Mandelkow, E., Mandelkow, E.M., Burn, D.J., Caparros-Lefebvre, D., Frey, K.A., de Yebenes, J.G., Gasser, T. et al. ReisensburgWorking Group for Tauopathies with Parkinsonism. (2009) Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol., 16, 297-309.
20. Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B.I., Geschwind, D.H., Bird, T.D., McKeel, D., Goate, A. et al. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science, 282, 1914-1917.
21. Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B.C., Christie, M.J., Napier, I.A. et al. (2010) Dendritic function of tau mediates amyloidbeta toxicity in Alzheimer's disease mouse models. Cell, 142, 387-397.
22. Cookson, M.R., Hardy, J. and Lewis, P.A. (2008) Genetic neuropathology of Parkinson's disease. Int. J. Clin. Exp. Pathol., 1, 217-231.
23. Giasson, B.I., Covy, J.P., Bonini, N.M., Hurtig, H.I., Farrer, M.J., Trojanowski, J.Q. and Van Deerlin, V.M. (2006) Biochemical and pathological characterization of Lrrk2. Ann. Neurol., 59, 315-322.
24. Gilks,W.P., Abou-Sleiman, P.M., Gandhi, S., Jain, S., Singleton, A., Lees, A.J., Shaw, K., Bhatia, K.P., Bonifati, V., Quinn, N.P. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, 365, 415-416.
25. Rajput, A., Dickson, D.W., Robinson, C.A., Ross, O.A., Dachsel, J.C., Lincoln, S.J., Cobb, S.A., Rajput, M.L. and Farrer, M.J. (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology, 67, 1506-1508.
26. Ujiie, S., Hatano, T., Kubo, S.I., Imai, S., Sato, S., Uchihara, T., Yagishita, S., Hasegawa, K., Kowa, H., Sakai, F. and Hattori, N. (2012) LRRK2 I2020 T mutation is associated with tau pathology. Parkinsonism Relat. Disord., 18, 819-823.
27. Farrer, M., Skipper, L., Berg, M., Bisceglio, G., Hanson, M., Hardy, J., Adam, A., Gwinn-Hardy, K. and Aasly, J. (2002) The tau H1 haplotype is associated with Parkinson's disease in the Norwegian population. Neurosci. Lett., 322, 83-86.
28. Kwok, J.B., Teber, E.T., Loy, C., Hallupp, M., Nicholson, G., Mellick, G.D., Buchanan, D.D., Silburn, P.A. and Schofield, P.R. (2004) Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann. Neurol., 55, 329-334.
29. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 41, 1308-1312.
30. Skipper, L.,Wilkes, K., Toft, M., Baker, M., Lincoln, S., Hulihan, M., Ross, O.A., Hutton, M., Aasly, J. and Farrer, M. (2004) Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet., 75, 669-677.
31. Lei, P., Ayton, S., Finkelstein, D.I., Spoerri, L., Ciccotosto, G.D., Wright, D.K.,Wong, B.X., Adlard, P.A., Cherny, R.A., Lam, L.Q. et al. (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med., 18, 291-295.
32. Lin, X., Parisiadou, L., Gu, X.L.,Wang, L., Shim, H., Sun, L., Xie, C., Long, C.X., Yang, W.J., Ding, J. et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alphasynuclein. Neuron, 64, 807-827.
33. Daher, J.P., Pletnikova, O., Biskup, S., Musso, A., Gellhaar, S., Galter, D., Troncoso, J.C., Lee, M.K., Dawson, T.M., Dawson, V.L. and Moore, D.J. (2012) Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet., 21, 2420-2431.
34. Skibinski, G.L., Nakamura, K., Cookson, M.R. and Finkbeiner, S. (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci., 34, 418-433.
35. Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R.E., Langston,W., Palmer, T.D. and Pera, R.R. (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell, 8, 267-280.
36. Lichtenberg, M., Mansilla, A., Zecchini, V.R., Fleming, A. and Rubinsztein, D.C. (2011) The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis., 2, e196.
37. Kondo, K., Obitsu, S. and Teshima, R. (2011) α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol. Pharm. Bull., 34, 1078-1083.
38. Li, Y., Liu, W., Oo, T.F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci., 12, 826-828.
39. Melrose, H.L., Dächsel, J.C., Behrouz, B., Lincoln, S.J., Yue, M., Hinkle, K.M., Kent, C.B., Korvatska, E., Taylor, J.P., Witten, L. et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis., 40, 503-517.
40. Dusonchet, J., Kochubey, O., Stafa, K., Young, S.M. Jr., Zufferey, R., Moore, D.J., Schneider, B.L. and Aebischer, P. (2011) Arat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J. Neurosci., 31, 907-912.
41. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587-593.
42. Gillardon, F. (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J. Neurochem., 110, 1514-1522.
43. Zach, S., Felk, S. and Gillardon, F. (2010) Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS ONE, 5, e13191.
44. Lin, C.H., Tsai, P.I., Wu, R.M. and Chien, C.T. (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3β. J. Neurosci., 30, 13138-13149.
45. Ferree, A., Guillily, M., Li, H., Smith, K., Takashima, A., Squillace, R., Weigele, M., Collins, J.J. and Wolozin, B. (2012) Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener. Dis., 10, 238-241.
46. Di Domenico, F.L., Sultana, R., Ferree, A., Smith, K., Barone, E., Perluigi,M., Coccia, R., Pierce,W., Cai, J.,Mancuso, C. et al. (2012) Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease. Antioxid. Redox. Signal., 17, 1490-1506.
47. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q. and Lee, V. M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron, 53, 337-351.
48. Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N.N., Yang, L., Starkov, A.A. and Beal, F. (2011) Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J., 25, 4063-4072.
49. Takeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T. et al. (2011) P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS ONE, 6, e21050.
50. Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci., 11, 791-797.
51. Gorbatyuk, O.S., Li, S., Sullivan, L.F., Chen,W., Kondrikova, G., Manfredsson, F.P., Mandel, R.J. and Muzyczka, N. (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl Acad. Sci. USA, 105, 763-768.
52. Carballo-Carbajal, I.L., Weber-Endress, S., Rovelli, G., Chan, D., Wolozin, B., Klein, C.L., Patenge, N., Gasser, T. and Kahle, P.J. (2010) Leucine-rich repeat kinase 2 induces alphasynuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal., 22, 821-827.
53. Giasson, B.I., Forman, M.S., Higuchi,M., Golbe, L.I., Graves, C.L., Kotzbauer, P.T., Trojanowski, J.Q. and Lee, V.M. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science, 300, 636-640.
54. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.Q. and Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, 316, 750-754.
55. Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P. and Ferreira, A. (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA, 99, 6364-6369.
56. Taes, I., Goris, A., Lemmens, R., van Es, M.A., van den Berg, L.H., Chio, A., Traynor, B.J., Birve, A., Andersen, P., Slowik, A. et al. (2010) Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse. Neurology, 74, 1687-1693.
57. Herzig, M.C., Bidinosti, M., Schweizer, T., Hafner, T., Stemmelen, C.,Weiss, A., Danner, S., Vidotto, N., Stauffer, D., Barske, C. et al. (2012) High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS ONE, 7, e36581.
58. Morris, M., Koyama, A., Masliah, E. and Mucke, L. (2011) Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS ONE, 6, e29257.
59. de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, G.A., Spires-Jones, T.L. and Hyman, B.T. (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron, 73, 685-697.